|
|
Project Number
|
Source
|
Project Title
|
Principal Investigator
|
Organization
|
Fiscal Year
|
Total Award
|
|
1
|
1R41AA010172-01
|
NIH
|
Development Of Herbal Suppressors For Alcohol Intake
|
David Yue-Wei Lee
|
Natural Pharmacia International, Inc.
|
1994
|
|
|
2
|
1R41AA011038-01
|
NIH
|
Sialic Acid-Deficient Apoj (Sdj)--Alcohol Intake Marker
|
Raj M. Lakshman
|
Bioprobes, Inc.
|
1996
|
|
|
3
|
1R41AA014312-01A1
|
NIH
|
Virtual Reality Cue Reactivity For Alcohol Dependence
|
Patrick Shannon Bordnick
|
Virtually Better, Inc.
|
2004
|
$149,903
|
|
4
|
1R41AA014449-01
|
NIH
|
Transitions: High School Alcohol Prevention
|
David L. Wyrick
|
Tanglewood Research, Inc.
|
2003
|
$100,000
|
|
5
|
1R41AA014554-01
|
NIH
|
Transgenic Plant Cells As Source Of Hepatoprotective Dr
|
John M. Littleton
|
Naprogenix, Inc
|
2003
|
$100,000
|
|
6
|
1R41AA014555-01
|
NIH
|
Application Of Plant Genomics To Alcoholic Brain Damage
|
John M. Littleton
|
Naprogenix, Inc
|
2004
|
$97,370
|
|
7
|
1R41AA014567-01
|
NIH
|
Naturally Occurring Agent For Alcohol Liver Diseases
|
David Yue-Wei Lee
|
Natural Pharmacia International, Inc.
|
2003
|
$222,677
|
|
8
|
1R41AA015475-01
|
NIH
|
Potential Anti-Relapse Drugs: A Plant Genomics Approach
|
John M. Littleton
|
Naprogenix, Inc
|
2004
|
$107,107
|
|
9
|
1R41AA015480-01
|
NIH
|
Farnesol Analogues As Novel Treatment Of Alcoholism
|
Jean-baptiste O. Roullet
|
Columbia Biotechnologies Corporation
|
2005
|
$99,987
|
|
10
|
1R41AA016029-01
|
NIH
|
New Opioids For Alcoholism
|
John R. Cashman
|
Behavioral Pharma, Inc.
|
2006
|
$161,500
|
|
11
|
1R41AA016030-01
|
NIH
|
A Stage-Based Tailored Support Tool For Alcohol Counsel
|
Scott M. Strayer
|
Silverchair Science+communication, Inc.
|
2006
|
$149,908
|
|
12
|
1R41AA016228-01
|
NIH
|
Biomarker Of Cognitive Impairment In Chronic Alcoholism
|
Samuel Gershon
|
Phfr, Inc.
|
2006
|
$100,370
|
|
13
|
1R41AA016235-01A1
|
NIH
|
Fetal Alcohol Spectrum Disorders: A Science-Based Prevention Curriculum
|
Kathleen Sulik
|
Science Learning Resources, Inc.
|
2007
|
$99,997
|
|
14
|
1R41AA016460-01
|
NIH
|
Device For Acamprosate Transcutaneous Delivery To Reduce Alcohol Consumption.
|
Robert M. Swift
|
Technova Corporation
|
2006
|
$149,998
|
|
15
|
1R41AA016499-01A1
|
NIH
|
Transdermal Cannabidiol Delivery For Alcohol-Induced Neurodegeneration
|
Kimberly Nixon
|
Alltranz, Inc.
|
2007
|
$100,565
|
|
16
|
1R41AA016500-01
|
NIH
|
Nasal Delivery Of Naltrexone For Treatment Of Alcoholism
|
Daniel Paul Wermeling
|
Intranasal Technology, Inc.
|
2006
|
$100,000
|
|
17
|
1R41AA016990-01A1
|
NIH
|
Recognition And Referral Skills For Ras-Alcohol And Other Drug Problems
|
Dennis L. Thombs
|
Phase 5, Inc.
|
2008
|
$139,309
|
|
18
|
1R41AA020451-01A1
|
NIH
|
Computerized Alcohol Misuse Intervention With Micro-Targeted Normative Feedback
|
Diana Howard Caldwell
|
Research Circle Associates, Llc
|
2011
|
$114,674
|
|
19
|
1R41AG012570-01A1
|
NIH
|
Sod/Catalase--Mimics In Neurodegenerative Diseases
|
Michel Baudry
|
Eukarion, Inc.
|
1995
|
|
|
20
|
1R41AG012572-01A1
|
NIH
|
Detection Of Alzheimer Specific Proteins In Csf
|
Thomas A. Campbell
|
Isolab, Inc.
|
1995
|
|
|
21
|
1R41AG012573-01
|
NIH
|
Low Cost Patient Locator System For Geriatric Wandering
|
Steen A. Parl
|
Signatron Technology Corporation
|
1994
|
|
|
22
|
1R41AG012576-01
|
NIH
|
Human Neurons In Vitro--Characterization Of Receptors
|
Dinah W. Sah
|
Signal Pharmaceuticals, Llc
|
1994
|
|
|
23
|
1R41AG013334-01
|
NIH
|
Dehydroepiandrosterone Treatment Of Alzheimers Disease
|
Paul J. Conlon
|
Neurocrine Biosciences, Inc.
|
1995
|
|
|
24
|
1R41AG013335-01
|
NIH
|
Trisomy 21 And A Potential Test For Alzheimers Disease
|
Lisa N. Geller
|
Genica Pharmaceuticals Corporation
|
1995
|
|
|
25
|
1R41AG013582-01A2
|
NIH
|
Research On New Methods Of Retirement Planning
|
B. Douglas Bernheim
|
Economic Security Planning, Inc.
|
1997
|
|